- Gross margins increased significantly to 59.2% from 53.6% in fiscal
2006.
- Excluding the impact of the sale of the surgical portfolio, the net
loss for 2007 was $29.2 million or a drop of 2.4% as compared to
$30.0 for 2006. Including the gain from selling the surgical
portfolio the net loss ended at $19.0 million.
- Overall operating burn increased marginally from $19.8 million in
2006 to $20.3 million in 2007.
- A total of 162 patients have been enrolled to date in our STOP AF IDE
pivotal trial. This study continues to be the fastest enrolling AFib
trial in the US. At the current enrollment rate per center we will
reach full enrollment by April 2008. This keeps this key program on
track for late 2009 approval by the FDA.
- There is a growing body of strong clinical evidence around our Arctic
Front system. In various studies in US and Europe, the system lives
up to its expectations and provides solid 12-month outcomes and no
permanent side effects in Paroxysmal AFib patients in a relatively
simple procedure.
"The past year has been packed with positive changes for CryoCath. More
than ever, we are now focused on commercialization and growth," said Jan
Keltjens, President & CEO of CryoCath. "Undoubtedly, the sale of the
surgical products division at the end of Q3 was the pivotal initiative in
this respect, enabling us to concentrate fully on the huge potential
offered by the electrophysiology market and atrial fibrillation, in
particular. Our focus is on obtaining US approval for our revolutionary
Arctic Front system and rapid, profitable growth in Europe. In both areas,
we made solid progress in 2007. In the last couple of months of 2007 we
were able to resolve supply constraints for Arctic Front and embarked on a
solid commercial roll-out plan in Europe. As a result, Arctic Fron
'/>"/>
| SOURCE CryoCath Technologies Inc. Copyright©2007 PR Newswire. All rights reserved |